Dow Jones Industrial Average
) is trading down 67 points (-0.5%) at 12,586 as of Tuesday, Jan 31, 2012, 11:40 a.m. ET. During this time, 277.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 818.6 million. The NYSE advances/declines ratio sits at 1,316 issues advancing vs. 1,555 declining with 124 unchanged.
Holding back the Dow today is
), which is lagging the broader Dow index with a 27-cent decline (-1.3%) bringing the stock to $21.31. This single loss is lowering the Dow Jones Industrial Average by 2.04 points or roughly accounting for 3% of the Dow's overall loss. Volume for Pfizer currently sits at 28 million shares traded vs. an average daily trading volume of 43.5 million shares.
Pfizer has a market cap of $166.5 billion and is part of the
industry. Shares are down 0.3% year to date as of Monday's close. The stock's dividend yield sits at 4.1%.
Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company has a P/E ratio of 16.9, above the average drugs industry P/E ratio of 14.9 and below the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Pfizer Ratings Report.